Patents by Inventor Robert V. TIGHE, III

Robert V. TIGHE, III has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CD137 ANTIBODIES AND PD-1 ANTAGONISTS AND USES THEREOF
    Publication number: 20240002525
    Abstract: The present disclosure relates to combinations of antibodies, or antigen-binding fragments thereof, that bind to CD137, and PD-1 antagonists. The disclosure also relates to methods for treating or ameliorating one or more symptoms of a disease, such as cancer, by administering the combination.
    Type: Application
    Filed: May 25, 2023
    Publication date: January 4, 2024
    Applicant: Compass Therapeutics LLC
    Inventors: Ugur Eskiocak, Robert V. Tighe, III
  • CD137 antibodies and tumor antigen-targeting antibodies and uses thereof
    Patent number: 11851497
    Abstract: The present disclosure relates to methods for treating or ameliorating one or more symptoms of a disease, such as cancer, by administering combinations of antibodies, or antigen-binding fragments thereof, that bind to CD137, and tumor antigen-targeting antibodies.
    Type: Grant
    Filed: November 20, 2018
    Date of Patent: December 26, 2023
    Assignee: COMPASS THERAPEUTICS LLC
    Inventors: Robert V. Tighe, III, Ugur Eskiocak
  • Agonist antibodies that bind human CD137 and uses thereof
    Patent number: 11752207
    Abstract: The present disclosure relates to, inter alia, compounds (e.g., antibodies, or antigen-binding fragments thereof) that bind to an epitope of CD137 and agonize CD137, and to use of the compounds in methods for treating, or ameliorating one or more symptoms of, cancer.
    Type: Grant
    Filed: June 8, 2020
    Date of Patent: September 12, 2023
    Assignee: Compass Therapeutics LLC
    Inventors: Piotr Bobrowicz, Paul Widboom, Michael March Schmidt, Jason M. Lajoie, Robert V. Tighe, III, Cheuk Lun Leung, Ugur Eskiocak
  • CD137 antibodies and PD-1 antagonists and uses thereof
    Patent number: 11718679
    Abstract: The present disclosure relates to combinations of antibodies, or antigen-binding fragments thereof, that bind to CD137, and PD-1 antagonists. The disclosure also relates to methods for treating or ameliorating one or more symptoms of a disease, such as cancer, by administering the combination.
    Type: Grant
    Filed: October 31, 2018
    Date of Patent: August 8, 2023
    Assignee: Compass Therapeutics LLC
    Inventors: Ugur Eskiocak, Robert V. Tighe, III
  • CD137 ANTIBODIES AND PD-1 ANTAGONISTS AND USES THEREOF
    Publication number: 20210221902
    Abstract: The present disclosure relates to combinations of antibodies, or antigen-binding fragments thereof, that bind to CD137, and PD-1 antagonists. The disclosure also relates to methods for treating or ameliorating one or more symptoms of a disease, such as cancer, by administering the combination.
    Type: Application
    Filed: October 31, 2018
    Publication date: July 22, 2021
    Inventors: Ugur Eskiocak, Robert V. Tighe, III
  • AGONIST ANTIBODIES THAT BIND HUMAN CD137 AND USES THEREOF
    Publication number: 20200306374
    Abstract: The present disclosure relates to, inter alia, compounds (e.g., antibodies, or antigen-binding fragments thereof) that bind to an epitope of CD137 and agonize CD137, and to use of the compounds in methods for treating, or ameliorating one or more symptoms of, cancer.
    Type: Application
    Filed: June 8, 2020
    Publication date: October 1, 2020
    Inventors: Piotr Bobrowicz, Paul Widboom, Michael March Schmidt, Jason M. Lajoie, Robert V. Tighe, III, Cheuk Lun Leung, Ugur Eskiocak
  • CD137 ANTIBODIES AND TUMOR ANTIGEN-TARGETING ANTIBODIES AND USES THEREOF
    Publication number: 20200308293
    Abstract: The present disclosure relates to methods for treating or ameliorating one or more symptoms of a disease, such as cancer, by administering combinations of antibodies, or antigen-binding fragments thereof, that bind to CD137, and tumor antigen-targeting antibodies.
    Type: Application
    Filed: November 20, 2018
    Publication date: October 1, 2020
    Inventors: Robert V. Tighe, III, Ugur Eskiocak
  • Agonist antibodies that bind human CD137 and uses thereof
    Patent number: 10716851
    Abstract: The present disclosure relates to, inter alia, compounds (e.g., antibodies, or antigen-binding fragments thereof) that bind to an epitope of CD137 and agonize CD137, and to use of the compounds in methods for treating, or ameliorating one or more symptoms of, cancer.
    Type: Grant
    Filed: September 6, 2018
    Date of Patent: July 21, 2020
    Assignee: Compass Therapeutics LLC
    Inventors: Piotr Bobrowicz, Paul Widboom, Michael March Schmidt, Jason M. Lajoie, Robert V. Tighe, III, Cheuk Lun Leung, Ugur Eskiocak
  • AGONIST ANTIBODIES THAT BIND HUMAN CD137 AND USES THEREOF
    Publication number: 20200046833
    Abstract: The present disclosure relates to, inter alia, compounds (e.g., antibodies, or antigen-binding fragments thereof) that bind to an epitope of CD137 and agonize CD137, and to use of the compounds in methods for treating, or ameliorating one or more symptoms of, cancer.
    Type: Application
    Filed: October 30, 2019
    Publication date: February 13, 2020
    Inventors: Piotr BOBROWICZ, Paul WIDBOOM, Michael March SCHMIDT, Jason M. LAJOIE, Robert V. TIGHE, III, Cheuk Lun LEUNG, Ugur ESKIOCAK
  • Agonist antibodies that bind human CD137 and uses thereof
    Patent number: 10434175
    Abstract: The present disclosure relates to compounds (e.g., antibodies, or antigen-binding fragments thereof) that bind to an epitope of CD137 and agonize CD137, and to use of the compounds in methods for treating, or ameliorating one or more symptoms of, cancer.
    Type: Grant
    Filed: May 23, 2019
    Date of Patent: October 8, 2019
    Assignee: Compass Therapeutics LLC
    Inventors: Piotr Bobrowicz, Paul Widboom, Michael March Schmidt, Jason M. Lajoie, Robert V. Tighe, III, Cheuk Lun Leung, Ugur Eskiocak
  • AGONIST ANTIBODIES THAT BIND HUMAN CD137 AND USES THEREOF
    Publication number: 20190269776
    Abstract: The present disclosure relates to compounds (e.g., antibodies, or antigen-binding fragments thereof) that bind to an epitope of CD137 and agonize CD137, and to use of the compounds in methods for treating, or ameliorating one or more symptoms of, cancer.
    Type: Application
    Filed: May 23, 2019
    Publication date: September 5, 2019
    Inventors: Piotr Bobrowicz, Paul Widboom, Michael March Schmidt, Jason M. Lajoie, Robert V. Tighe, III, Cheuk Lun Leung, Ugur Eskiocak
  • AGONIST ANTIBODIES THAT BIND HUMAN CD137 AND USES THEREOF
    Publication number: 20190224315
    Abstract: The present disclosure relates to compounds (e.g., antibodies, or antigen-binding fragments thereof) that bind to an epitope of CD137 and agonize CD137, and to use of the compounds in methods for treating, or ameliorating one or more symptoms of, cancer.
    Type: Application
    Filed: April 3, 2019
    Publication date: July 25, 2019
    Inventors: Piotr Bobrowicz, Paul Widboom, Michael March Schmidt, Jason M. Lajoie, Robert V. Tighe, III, Cheuk Lun Leung, Ugur Eskiocak
  • Agonist antibodies that bind human CD137 and uses thereof
    Patent number: 10350292
    Abstract: The present disclosure relates to compounds (e.g., antibodies, or antigen-binding fragments thereof) that bind to an epitope of CD137 and agonize CD137, and to use of the compounds in methods for treating, or ameliorating one or more symptoms of, cancer.
    Type: Grant
    Filed: April 3, 2019
    Date of Patent: July 16, 2019
    Assignee: Compass Therapeutics LLC
    Inventors: Piotr Bobrowicz, Paul Widboom, Michael March Schmidt, Jason M. Lajoie, Robert V. Tighe, III, Cheuk Lun Leung, Ugur Eskiocak
  • Agonist antibodies that bind human CD137 and uses thereof
    Patent number: 10279039
    Abstract: The present disclosure relates to compounds (e.g., antibodies, or antigen-binding fragments thereof) that bind to an epitope of CD137 and agonize CD137, and to use of the compounds in methods for treating, or ameliorating one or more symptoms of, cancer.
    Type: Grant
    Filed: December 13, 2018
    Date of Patent: May 7, 2019
    Assignee: Compass Therapeutics LLC
    Inventors: Piotr Bobrowicz, Paul Widboom, Michael March Schmidt, Jason M. Lajoie, Robert V. Tighe, III, Cheuk Lun Leung, Ugur Eskiocak
  • Agonist antibodies that bind human CD137 and uses thereof
    Patent number: 10279038
    Abstract: The present disclosure relates to compounds (e.g., antibodies, or antigen-binding fragments thereof) that bind to an epitope of CD137 and agonize CD137, and to use of the compounds in methods for treating, or ameliorating one or more symptoms of, cancer.
    Type: Grant
    Filed: November 9, 2018
    Date of Patent: May 7, 2019
    Assignee: Compass Therapeutics LLC
    Inventors: Piotr Bobrowicz, Paul Widboom, Michael March Schmidt, Jason M. Lajoie, Robert V. Tighe, III, Cheuk Lun Leung, Ugur Eskiocak
  • Agonist antibodies that bind human CD137 and uses thereof
    Patent number: 10279040
    Abstract: The present disclosure relates to compounds (e.g., antibodies, or antigen-binding fragments thereof) that bind to an epitope of CD137 and agonize CD137, and to use of the compounds in methods for treating, or ameliorating one or more symptoms of, cancer.
    Type: Grant
    Filed: December 21, 2018
    Date of Patent: May 7, 2019
    Assignee: Compass Therapeutics LLC
    Inventors: Piotr Bobrowicz, Paul Widboom, Michael March Schmidt, Jason M. Lajoie, Robert V. Tighe, III, Cheuk Lun Leung, Ugur Eskiocak
  • AGONIST ANTIBODIES THAT BIND HUMAN CD137 AND USES THEREOF
    Publication number: 20190125866
    Abstract: The present disclosure relates to compounds (e.g., antibodies, or antigen-binding fragments thereof) that bind to an epitope of CD137 and agonize CD137, and to use of the compounds in methods for treating, or ameliorating one or more symptoms of, cancer.
    Type: Application
    Filed: December 21, 2018
    Publication date: May 2, 2019
    Inventors: Piotr BOBROWICZ, Paul WIDBOOM, Michael March SCHMIDT, Jason M. LAJOIE, Robert V. TIGHE, III, Cheuk Lun LEUNG, Ugur ESKIOCAK
  • AGONIST ANTIBODIES THAT BIND HUMAN CD137 AND USES THEREOF
    Publication number: 20190099488
    Abstract: The present disclosure relates to compounds (e.g., antibodies, or antigen-binding fragments thereof) that bind to an epitope of CD137 and agonize CD137, and to use of the compounds in methods for treating, or ameliorating one or more symptoms of, cancer.
    Type: Application
    Filed: December 13, 2018
    Publication date: April 4, 2019
    Inventors: Piotr Bobrowicz, Paul Widboom, Michael March Schmidt, Jason M. Lajoie, Robert V. Tighe, III, Cheuk Lun Leung, Ugur Eskiocak
  • AGONIST ANTIBODIES THAT BIND HUMAN CD137 AND USES THEREOF
    Publication number: 20190060454
    Abstract: The present disclosure relates to compounds (e.g., antibodies, or antigen-binding fragments thereof) that bind to an epitope of CD137 and agonize CD137, and to use of the compounds in methods for treating, or ameliorating one or more symptoms of, cancer.
    Type: Application
    Filed: November 9, 2018
    Publication date: February 28, 2019
    Inventors: Piotr BOBROWICZ, Paul WIDBOOM, Michael March SCHMIDT, Jason M. LAJOIE, Robert V. TIGHE, III, Cheuk Lun LEUNG, Ugur ESKIOCAK
  • MULTISPECIFIC IMMUNOMODULATORY ANTIGEN-BINDING CONSTRUCTS
    Publication number: 20190031785
    Abstract: Provided herein are multispecific immunomodulatory antigen-binding constructs (MIACs) and compositions comprising the constructs. Also provided are methods of using the constructs and methods of making the constructs.
    Type: Application
    Filed: January 13, 2017
    Publication date: January 31, 2019
    Inventors: Thomas Joseph SCHUETZ, Piotr BOBROWICZ, Helen SABZEVARI, Michael March SCHMIDT, Robert V. TIGHE, III, Simon METENOU